Phio Pharma Q3 net loss $2.4M; PH-762 trial 100% tumor clearance at max dose

Phio Pharmaceuticals Corp.

Net loss $2.4M for Q3 2025 vs $1.5M in Q3 2024; R&D expenses $1.2M, G&A $1.3M.
Phase 1b PH-762 trial: 100% tumor clearance (complete response) in one patient at max dose, >90% in second, >50% in third.
Cumulative pathologic results in 16 cSCC patients: 6 complete, 2 near complete, 2 partial responses; no dose-limiting toxicities.
November 2025 warrant inducement financing expected to raise ~$12.1M, extending cash runway into first half 2027.
Cash and equivalents $10.7M at Sep 30, 2025; estimated $21.3M as of release date.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.